Clinical Performance of the OxyAqua Daily Disposable Silicone Hydrogel Soft Contact Lens

Myopia Clinical Trial

Official title:

A Prospective Randomized Controlled Study to Evaluate the Clinical Performance of OxyAqua Silicone Hydrogel Soft Contact Lens

Clinical Trial Details — Status: Completed

Administrative data

• NCT number: NCT03139201
• Other study ID #: 1040625M
• Status: Completed
• Phase: N/A
• First received: April 29, 2017
• Last updated: May 2, 2017
• Start date: September 21, 2016
• Est. completion date: December 8, 2016

Study information

• Verified date: April 2017
• Source: Visco Vision Inc.
• Contact: n/a
• Is FDA regulated: No
• Study type: Interventional

Clinical Trial Summary

The objective of this study is to demonstrate that the OxyAqua silicone hydrogel soft contact lens could be prescribed as a supportive care for myopes.

Description:

This is a double blind randomized control study to evaluate a daily disposable contact lens. It is planned to have 30 evaluable subjects at least divided evenly among 3 independent PIs from one hospital. Each PI will enroll 12 subjects at least. The ration of evaluable test subjects to control subjects will be 2 to 1. The study lens will be dispensed randomly to subjects who have normal ocular health and conform to a set of criteria. It is necessary to wear the lens 8 hours a day and 5 days a week at least and follow up for one month (30 days). Data will be collected at baseline, 1 week, 2 week and 4 week of daily disposable modality including Adverse Reactions, Slit-lamp findings and Symptoms, Problems, and Complaints, vision acuity, keratometry change and reason for discontinuation.

Recruitment information / eligibility

• Status: Completed
• Enrollment: 36
• Est. completion date: December 8, 2016
• Est. primary completion date: December 8, 2016
• Accepts healthy volunteers: No
• Gender: All
• Age group: 20 Years and older

Eligibility

Inclusion Criteria:

• Subjects should have normal eyes and use no ocular medications. They may have worn contact lenses previously, provided their eyes are shown to be normal at the start of the investigation. A normal eye is defined as having the following characteristics:

1. No anterior segment infection, inflammation or abnormality.

2. No other active ocular or systemic disease that would contraindicate contact lens wear; and

3. No medications that would contraindicate contact lens wear.

• VA correctable to 0.1 LogMAR or better, with spherical lenses ranging in power from

• 1.00 to -10.00 D myopia, astigmatism less than 2.00 D

• Willing to comply with all study procedures and be available for the duration of the study.

• Provide signed and dated informed consent form.

Exclusion Criteria:

• Have history of allergies that would contraindicate "normal" contact lens wear.

• Have other active ocular or systemic disease such as, but not limited to: anterior uveitis (past or present), glaucoma, Sjögren's syndrome, lupus erythematosus, sclerodermas, keratoconus or type II diabetes, slip lamp findings greater than grade I (such as cornea or interstitial edema).

• Have medications that would contraindicate contact lens wear.

• Have had any cornea surgery.

• Currently pregnant (to the best of the subject's knowledge), is lactating or is planning a pregnancy within the next 1 month.

• Any active participation in another clinical trial within 30 days prior to this study.

• The presence of clinically significant (grade 3 or 4) anterior segment abnormalities; inflammations such as iritis; or any infection of the eye, lids, or associated structures.

• A known history of corneal hypoesthesia (reduced corneal sensitivity), corneal ulcer, corneal infiltrates or fungal infections.

• A history of papillary conjunctivitis that has interfered with contact lens wear.

• No monocular or monovision fits.

• Alcoholic or Drug Abused.

Related Conditions & MeSH terms

• Myopia

Intervention

Device:
• OxyAqua
OxyAqua (olifilcon D) silicone hydrogel soft contact lens
• Si-Hy
Si-Hy (oliflcon B) silicone hydrogel soft contact lens

Locations

Country	Name	City	State
n/a

Sponsors (1)

Lead Sponsor	Collaborator
Visco Vision Inc.

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	Log MAR visual acuity (VA)	the visual acuity corrected with contact lens could reach 0.1 or better	one month
Secondary	Any slit lamp findings > grade 2	slit lamp findings on all dispensed eyes over all follow-up visits. Measured on a scale of 0-4 with 0=no findings and 4=sever findings.	over all follow-up visits for the 1 month
Secondary	Subjective response to comfort, symptoms and complaints	subjective ratings of comfort, symptom and complaints using a scale of 0=severe stinging/Burning to 5=No stinging/Burning for each eye	over all follow-up visits for the 1 month